The U.S. Senate is finally slated to vote today on a bill that would expand federal funding for embryonic stem cell research. If passed, the bill would lift a presidential mandate set in 2001 that severely limited federal funding of stem cell research. This reversal would be a huge boon to stem cell scientists, who have been forced to turn to private or state sources for funding.
President Bush has repeatedly vowed to veto the bill, though, which the Senate is expected to pass on Tuesday. Its more optimistic proponents hope the bill will garner the 67 votes needed to override a veto. However, the bill fell 50 votes short of a veto-proof margin when it was passed in the House last year.
An article in the New York Times gives an informative outline of the bill, its supporters, and its opponents. Here’s the bill. For more on this field, check out Technology Review’s special report on stem cell science, and especially TR correspondent Charles Mann’s feature “Braving Medicine’s Frontier” (September 2005,) which takes a look at how President Bush’s 2001 mandate crippled the field. – By Emily Singer
The big new idea for making self-driving cars that can go anywhere
The mainstream approach to driverless cars is slow and difficult. These startups think going all-in on AI will get there faster.
Inside Charm Industrial’s big bet on corn stalks for carbon removal
The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.
The hype around DeepMind’s new AI model misses what’s actually cool about it
Some worry that the chatter about these tools is doing the whole field a disservice.
The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.